In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: ResMed’s current price at $188.63 is 49.4% below its PERT-weighted fair value of $281.81, indicating potential undervaluation supported by strong confidence levels. High financial health scores and robust discounted cash flow valuation contrast with Monte Carlo’s high volatility and 33.3% downside risk, reflecting both growth opportunity and elevated uncertainty. The broad valuation range underscores diverse scenario outcomes, suggesting considerable risk-reward variability.